EBV-DNA viral load (quantitative PCR, plasma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-EBV-DNA |
|---|---|
| Type | Biomarker |
| Aliases | EBV PCREBV viral loadEBV-DNA quantitative loadPlasma EBV-DNAВірусне навантаження EBV-DNA (кількісна ПЛР, плазма) |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | viral_load |
|---|---|
| Measurement | MethodReal-time quantitative PCR for EBV-DNA on cell-free plasma (preferred) or whole blood. Plasma EBV-DNA reflects active viral replication and tumor lysis; whole-blood EBV-DNA includes latent virus in B-cells and is less specific for active disease. Standardized in IU/mL via WHO international standard. UnitsIU/mL (or copies/mL with assay-specific conversion) Typical range
|
| Related biomarkers | BIO-EBV-STATUS BIO-HIV-STATUS |
Notes
Companion to BIO-EBV-STATUS (qualitative tissue EBER-ISH). EBV-DNA is the *quantitative* serum marker used for: - **Extranodal NK/T nasal-type lymphoma**: pre-treatment baseline; monitoring during SMILE / DDGP / asparaginase-based regimens; post-treatment surveillance. Rising EBV-DNA on therapy correlates with poor response; persistent post-treatment positivity predicts relapse. - **PTLD**: EBV-driven PTLD shows EBV-DNA load decrease with rituximab + reduced immunosuppression; trend is response surrogate. - **HIV-associated EBV+ DLBCL / plasmablastic / primary effusion**: contextual; not standardly used for treatment decisions. - **Post-HSCT monitoring**: weekly EBV-DNA used to detect early PTLD risk; preemptive rituximab if doubling. Wired into: ALGO-NK-T-NASAL-1L (notes only — full Monitoring entity with thresholds and frequency to be authored). reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals
Used By
Indications
IND-NK-T-NASAL-1L-P-GEMOX- IND-NK-T-NASAL-1L-P-GEMOXIND-NK-T-NASAL-1L-SMILE- IND-NK-T-NASAL-1L-SMILEIND-PTLD-1L-REDUCE-IS- IND-PTLD-1L-REDUCE-IS
Questionnaires
QUEST-NK-T-NASAL-1L-STUB- Extranodal NK/T-Cell Lymphoma, Nasal Type — first lineQUEST-PTLD-1L-STUB- Post-Transplant Lymphoproliferative Disorder — first line